Imperial College London

MrJosephEliahoo

Faculty of MedicineSchool of Public Health

Statistical Consultant
 
 
 
//

Contact

 

j.eliahoo Website

 
 
//

Assistant

 

Mrs Krupa Shukla +44 (0)20 7594 1754

 
//

Location

 

//

Summary

 

Publications

Publication Type
Year
to

16 results found

Youssaf A, Kim J, Eliahoo J, Taylor-Robinson S, Khan Set al., 2019, Ablative therapy for unresectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis, Journal of Clinical and Experimental Hepatology, Vol: 9, Pages: 740-748, ISSN: 0973-6883

Background: Intrahepatic cholangiocarcinoma (iCCA) is usually a fatal malignancy with rising incidence globally. Surgical resection currently remains the only curative treatment. However, as only a minority of iCCA are amenable to resection, new therapeutic modalities are needed. Aims: Our aims were to systematically review and perform a meta-analysis on the existing literature regarding the use of ablative therapies in iCCA; and to assess their efficacy as a treatment modality by calculating pooled survival results and investigate associations between prognostic factors and survival. Methods: A comprehensive search of the PubMed database for relevant articles was performed. Studies assessing survival in patients with iCCA undergoing ablation were included. Data were extracted on patient, tumour and treatment characteristics and survival. Random effects meta-analysis was used to pool the data. Galbraith plots were used to investigate heterogeneity; bubble plots were formulated using regression-based meta-analysis. Results: 10 studies were included in the final analysis, yielding an aggregate of 206 patients (69.5% male, median age 51.2-72.5) and 320 tumours. 70.4% of patients were recurrent cases of iCCA and 29.6% primary iCCA. Median overall survival ranged from 8.7 to 52.4 months. Pooled survival rates for 1, 3 and 5-year survival were 76% (95% CI: 68-83%), 33% (21-44%) and 16% (7-26%), respectively. No significant association was found between the median age, number of tumours or median tumour size and 1-year survival. Conclusion: Ablative therapies display promising potential as treatment modalities for iCCA. However, further research is necessary to validate these findings.

Journal article

Francis-Morris A, Mackie NE, Eliahoo J, Ramzan F, Fidler S, Pollock KMet al., 2019, Compromised CD4:CD8 ratio recovery in people living with HIV aged over 50 years: an observational study, HIV Medicine, Vol: 21, Pages: 109-118, ISSN: 1464-2662

ObjectivesPersistent CD4:CD8 ratio inversion (< 1) is associated with mortality in older people. We investigated the interaction of the effects of baseline CD8 count and age at HIV diagnosis on CD4:CD8 ratio recovery with antiretroviral therapy (ART).MethodsAn observational study (1 January 2007 to 31 December 2016) was carried out using routinely collected data from the HIV outpatient services at Imperial College Healthcare NHS Trust, London, UK. CD4 and CD8 counts, prior to and during ART, treatment during primary HIV infection (PHI) and HIV‐1 viral load were included in univariate and multivariate analyses using Cox proportional hazard regression.ResultsData were included for 876 patients starting ART, where HIV suppression was achieved. Of these patients, 741 of 876 (84.6%) were male and 507 of 876 (57.9%) were Caucasian. The median time on ART was 38 [interquartile range (IQR) 17–66] months. CD8 count change on ART was bidirectional; low CD8 counts (≤ 600 cells/μL) increased and high CD8 counts (> 900 cells/μL) decreased. The median pre‐ART CD4:CD8 ratio was 0.41 (IQR 0.24–0.63), and recovery (≥ 1) occurred in 274 of 876 patients (31.3%). Pre‐ and post‐ART CD4:CD8 ratios were lower in those aged > 50 years compared with young adults aged 18–30 years (P < 0.001 and P = 0.002, respectively). After adjustment, younger age at HIV diagnosis (P < 0.001) and treatment during PHI (P < 0.001) were favourable for CD4:CD8 ratio normalization.ConclusionsOlder age (> 50 years) at HIV diagnosis was associated with persistent CD4:CD8 ratio inversion, whereas treatment of PHI was protective. These findings confirm the need for testing and early treatment of people aged > 50 years, and could be used in a risk management algorithm for enhanced surveillance.

Journal article

Webster CE, Clasper J, Stinner DJ, Eliahoo J, Masouros SDet al., 2018, Characterization of Lower Extremity Blast Injury, MILITARY MEDICINE, Vol: 183, Pages: E448-E453, ISSN: 0026-4075

Journal article

Hargreaves S, Seedat F, Car J, Escombe R, Hasan S, Eliahoo J, Friedland JSet al., 2014, Screening for latent TB, HIV, and hepatitis B/C in new migrants in a high prevalence area of London, UK: a cross-sectional study, BMC INFECTIOUS DISEASES, Vol: 14, ISSN: 1471-2334

Journal article

Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, Smith J, McClure MO, Karayiannis Pet al., 2011, Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men, GUT, Vol: 60, Pages: 837-845, ISSN: 0017-5749

Journal article

Taher SE, Inder JW, Soltan SA, Eliahoo J, Edmonds DK, Bennett PRet al., 2011, Prostaglandin E2 vaginal gel or tablets for the induction of labour at term: a randomised controlled trial, BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 118, Pages: 719-725, ISSN: 1470-0328

Journal article

Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NMet al., 2010, Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia, CLINICAL ENDOCRINOLOGY, Vol: 73, Pages: 369-374, ISSN: 0300-0664

Journal article

Mehta SR, Thomas EL, Patel N, Crofton ME, McCarthy J, Eliahoo J, Morin SX, Fitzpatrick J, Durighel G, Goldstone AP, Johnston DG, Bell JD, Taylor-Robinson SDet al., 2010, Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification, HEPATOLOGY RESEARCH, Vol: 40, Pages: 399-406, ISSN: 1386-6346

Journal article

Morin SHX, Cobbold JFL, Lim AKP, Eliahoo J, Thomas EL, Mehta SR, Durighel G, Fitzpatrick J, Bell JD, Taylor-Robinson SDet al., 2009, Incidental findings in healthy control research subjects using whole-body MRI, EUROPEAN JOURNAL OF RADIOLOGY, Vol: 72, Pages: 529-533, ISSN: 0720-048X

Journal article

Tyrer P, Oliver-Africano P, Romeo R, Knapp M, Dickens S, Bouras N, Ahmed Z, Cooray S, Deb S, Murphy D, Hare M, Meade M, Reece B, Kramo K, Bhaumik S, Harley D, Regan A, Thomas D, Rao B, Karatela S, Lenotre L, Watson J, Soni A, Crawford M, Eliahoo J, North Bet al., 2009, Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID), HEALTH TECHNOLOGY ASSESSMENT, Vol: 13, Pages: 1-+, ISSN: 1366-5278

Journal article

Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Myra DM, McClure MOet al., 2009, Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV, AIDS, Vol: 23, Pages: 89-93, ISSN: 0269-9370

Journal article

Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N, Cooray S, Deb S, Murphy D, Hare M, Meade M, Reece B, Kramo K, Bhaumik S, Harley D, Regan A, Thomas D, Rao B, North B, Eliahoo J, Karatela S, Soni A, Crawford Met al., 2008, Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial., Lancet, Vol: 371, Pages: 57-63, ISSN: 1474-547X

BACKGROUND: Aggressive challenging behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared flexible doses of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second-generation antipsychotic), and placebo, in the treatment of this behaviour. METHODS: 86 non-psychotic patients presenting with aggressive challenging behaviour from ten centres in England and Wales, and one in Queensland, Australia, were randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29). Clinical assessments of aggression, aberrant behaviour, quality of life, adverse drug effects, and carer uplift (positive feelings about the care of the disabled person) and burden, together with total costs, were recorded at 4, 12, and 26 weeks. The primary outcome was change in aggression after 4 weeks' treatment, which was recorded with the modified overt aggression scale (MOAS). Analysis was by intention to treat. This study is registered as ISRCTN 11736448. FINDINGS: 80 patients had adherence of 80% or more to prescribed drug. Aggression decreased substantially with all three treatments by 4 weeks, with the placebo group showing the greatest change (median decrease in MOAS score after 4 weeks=9 [95% CI 5-14] for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6.5 [5-14] for haloperidol, 65% from baseline; p=0.06). Furthermore, although no important differences between the treatments were recorded, including adverse effects, patients given placebo showed no evidence at any time points of worse response than did patients assigned to either of the antipsychotic drugs. INTERPRETATION: Antipsychotic drugs should no longer be regarded as an acceptable routine treatment for aggressive challenging behaviour in people with intellectual disability.

Journal article

Soljak M, Majeed A, Eliahoo J, Dornhorst Aet al., 2007, Ethnic inequalities in the treatment and outcome of diabetes in three English Primary Care Trusts, Vol: 6, ISSN: 1475-9276

BACKGROUND:Although the prevalence of diabetes is three to five times higher in UK South Asians than Whites, there are no reports of the extent of ethnicity recording in routine general practice, and few population-based published studies of the association between ethnicity and quality of diabetes care and outcomes. We aimed to determine the association between ethnicity and healthcare factors in an English population.METHODS:Data was obtained in 2002 on all 21,343 diabetic patients registered in 99% of all computerised general practitioner (GP) practices in three NW London Primary Care Trusts (PCTs), covering a total registered population of 720,000. Previously practices had been provided with training, data entry support and feedback. Treatment and outcome measures included drug treatment and blood pressure (BP), total cholesterol and haemoglobin A1c (HbA1c) levels.RESULTS:Seventy per cent of diabetic patients had a valid ethnicity code. In the relatively older White population, we expected a smaller proportion with a normal BP, but BP differences between the groups were small and suggested poorer control in non-White ethnic groups. There were also significant differences between ethnic groups in the proportions of insulin-treated patients, with a smaller proportion of South Asians - 4.7% compared to 7.1% of Whites - receiving insulin, although the proportion with a satisfactory HbA1c was smaller- 25.6% compared to 37.9%.CONCLUSION:Recording the ethnicity of existing primary care patients is feasible, beginning with patients with established diseases such as diabetes. We have shown that the lower proportion of South Asian patients with good diabetes control, and who are receiving insulin, is at least partly due to poorer standards of care in South Asians, although biological and cultural factors could also contribute. This study highlights the need to capture ethnicity data in clinical trials and in routine care, to specifically investigate the reasons for these

Journal article

Hargreaves S, Friedland JS, Gothard P, Saxena S, Millington H, Eliahoo J, Le Feuvre P, Holmes Aet al., 2006, Impact on and use of health services by international migrants: questionnaire survey of inner city London A&E attenders, BMC HEALTH SERVICES RESEARCH, Vol: 6

Journal article

Saxena S, Eliahoo J, Majeed A, 2002, Socioeconomic and ethnic group differences in self reported health status and use of health services by children and young people in England: cross sectional study, BMJ-BRITISH MEDICAL JOURNAL, Vol: 325, Pages: 520-523, ISSN: 1756-1833

Journal article

Majeed A, Eliahoo J, Bardsley M, Morgan D, Bindman ABet al., 2002, Variation in coronary artery bypass grafting, angioplasty, cataract surgery, and hip replacement rates among primary care groups in London: association with population and practice characteristics, JOURNAL OF PUBLIC HEALTH MEDICINE, Vol: 24, Pages: 21-26, ISSN: 0957-4832

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00411739&limit=30&person=true